News & Events about Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) insider Pascal Deschatelets sold 12,000 shares of the businesss stock in a transaction dated Monday, January 9th. The stock was sold at an average price of $46.08, for a total transaction of $552,960.00. Following the sale, the ...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) insider Pascal Deschatelets sold 12,000 shares of the firms stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $46.08, for a total transaction of $552,960.00. Following the completion of the ...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) insider Federico Grossi sold 2,500 shares of the companys stock in a transaction on Thursday, January 5th. The stock was sold at an average price of $48.79, for a total value of $121,975.00. Following the sale, the insider now ...
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replaces Federico...
Latest Ratings for APLS
DateFirmActionFromTo Mar 2022Goldman SachsMaintainsBuy Mar 2022Raymond JamesMaintainsStrong Buy Jan 2022Raymond JamesMaintainsStrong Buy
View More Analyst Ratings for APLS
View the Latest Analyst Ratings
read more...